Contract Awards

Not specified

Direct Adjustment For The Acquisition Of I287- Infliximab Patients Under Treatment [100 Mg; Powder P/A Conc To Sol P/A Perf; Frs], U41- Ustecinumab [45 Mg/ 0.5 Ml; Sol Inj; Syringe] - Patients In Treatment, U42- Ustecinumab [90 Mg; Sol Inj; Syringe] - Patients In Treatment And U43- Ustecinumab [130 Mg; Sol Inj; Frs] - Patients In Treatment.